NI 2101
Alternative Names: NI-2101; NIBX-2101Latest Information Update: 28 Nov 2021
At a glance
- Originator Light Chain Bioscience
- Developer Light Chain Bioscience; Takeda
- Class Bispecific antibodies; Blood coagulation factors
- Mechanism of Action Factor IXa inhibitors; Factor X inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemophilia A